

Metabolic Glycoengineering-Driven 'Clickable' Nanoemulsions for Biomarker-Agnostic Tumour Targeting

NAON Nanoncology Unit



idris

INSTITUTO DE INVESTIGACIÓN SANITARIA
SANTIAGO DE COMPOSTELA

Jenifer García-Fernández^{1*}, Maria Iglesias Baleato^{1,2}, Iria Fontán Luis¹, María de la Fuente^{1,3,4}

¹ Nano-Oncology and Translational Therapeutics Group, Health Research Institute of Santiago de Compostela (IDIS), SERGAS, Santiago de Compostela, Spain

² Universidad de Santiago de Compostela (USC), Santiago de Compostela, Spain

³ Biomedical Research Networking Center on Oncology (CIBERONC), Madrid, Spain

⁴ DIVERSA Technologies SL, Santiago de Compostela, Spain


* Jenifer.Garcia.Fernandez@sergas.es

ciberonc

USC
UNIVERSIDADE DE SANTIAGO
DE COMPOSTELA

THE CHALLENGE

Triple-Negative Breast Cancer (TNBC)



- Highly heterogenous and resistant to treatment
- Lack of specific biomarkers
- Limited treatment options: surgery, radio/chemotherapy


Limitations Targeted Therapies

- Microenvironmental influences
- Dynamic biomarker expression
- Technological limitations
- Challenge in discriminating cancer Vs normal cells

INTRODUCTION

METABOLIC GLYCOENGINEERING (MGE)


MGE enables the selective installation of bioorthogonal azides on tumour cell glycans, exploiting altered glycan metabolism of cancer cells and generating artificial biomarkers for 'click' conjugation with functionalized nanocarriers




Selectively labelling of cancer cells as alternative for targeted therapies to agnostic-biomarker tumors

OUR STRATEGY

1. Azide labelling of cancer cells by MGE




2. Click conjugation via SPAAC with DBCO-functionalized Nanoemulsions



METHODS & RESULTS



1 Nanoemulsion Formulation



2 Physicochemical characterization


Table 1. Physicochemical characterization of SNS-DBCO at different DBCO concentrations in terms of hydrodynamic volume (size, nm), Polydispersity Index (PDI), and surface charge (Z-Potential, mV), measured by Dynamic Light Scattering (DLS) and Laser Doppler Anemometry (LDA).

SN	Molar ratio	[DBCO] (μM)	Size (nm)	PDI	Z-Potential (mV)
Vitamin E: Sphingomyelin: PEG2k-DBCO	1:0.1:0.01	16	86.9 ± 1.6	0.20 ± 0.10	-20.6 ± 3.3
	1:0.1:0.02	32	81.0 ± 1.7	0.26 ± 0.02	-23.0 ± 0.9
	1:0.1:0.04	64	71.1 ± 1.1	0.30 ± 0.02	-18.9 ± 1.9
	1:0.1:0.08	128	73.7 ± 1.3	0.30 ± 0.03	-21.2 ± 2.9
	1:0.1:0.1	160	96.7 ± 1.3	0.31 ± 0.12	-27.3 ± 2.6



- Small size (<100 nm), narrow distribution (PDI<0.2) and negatively charged formulations at all molar ratios (increasing DBCO concentration).
- SNS-DBCO exhibit a spherical morphology with sizes ranging from 70 - 100 nm, consistent with Dynamic Light Scattering (DLS) characterization.
- Colloidal stability in water under storage conditions (4°C) up to 1 month, and 24 hours in physiological simulating conditions (cell culture medium, 37°C)


3 'Click' reactivity in suspension




- Reaction conditions evaluated and optimized (ratio, temperature, medium, reaction time).
- 'Click' reactivity assessment completed with SNS-DBCO to further translation in vitro.

Optimal ratio DBCO:N3	DBCO Conjugation Efficiency	'Click' Reactivity Efficiency
5:1	88%	~70%

4 'Click' reactivity in vitro




Viability assays



No cytotoxicity detected

Internalization assays



↓ PEG-DBCO density → ↑ +N3/-N3 ratio

1:0.1:0.01 → best SNS-DBCO molar ratio for click-mediated targeting

Steric crowding of PEG chains may limit the accessibility of DBCO groups to cell-surface azides

Fig. 8. Fluorescence microscopy images of the 'click' reaction in MDA-MB-231 cells pre-treated with Ac4ManNAz (+N3) 100 μM for 48 h or without (-N3), after incubation with A. DBCO-Cy5 probe (red) at 1 μM for 30 minutes; B. SNS-DBCO-Cy5 (red) at 20 μM DBCO concentration for 30 minutes and 1 hour.

5 Highlights

- Development of DBCO-sphingomyelin nanoemulsions - SNS-DBCO with optimal physicochemical properties (<200 nm, PDI <0.2) successfully developed, highly biocompatible and stable for biomedical applications.
- Click reactivity assessment in suspension - SNS-DBCO exhibited high click reactivity (~70%) in suspension, with optimized formulation parameters (molar ratio, reaction time, media).
- Efficient cellular glycoengineering - MGE with Ac4ManNAz achieved efficient labelling of the tumour cell surface without compromising cell viability. The DBCO-N3 click interaction was validated in vitro as a precise and selective targeting strategy, supporting its potential for safer and more effective tumour-directed therapies.

6 Next steps

- Translation of the MGE strategy to other tumor cell lines (glioma model) to demonstrate the versatility of the approach.
- Validation of click reactivity in vitro with 3D tumor models.
- In vivo evaluation of the MGE labelling strategy in TNBC/glioma models.
- Therapeutic assessment of drug-loaded SNS-DBCO in TNBC.

ACKNOWLEDGEMENTS